Objective To observe the effects of pertuzumab on immune indexes and tumor markers in pa-tients with breast cancer.Methods Eighty patients with breast cancer were included in the study from March 2021 to September 2022.The patients were grouped by random number table method in randomized method.The control group(n=40)was treated with trastuzumab+docetaxel+carboplatin,and the obser-vation group(n=40)was treated with pertuzumabon the basis of the control group.The levels of immune indexes,tumor markers and adverse reactions were compared before treatment,after 2 cycles of treatment and after 6 cycles of treatment.At the same time,stratified analysis was conducted according to the patho-logical examination results to confirm the therapeutic effect.Results The immune indexes of the two groups before treatment were compared(P>0.05).After 2 cycles of treatment and 6 cycles of treatment,the levels of CD3+,CD4+and CD4+/CD8+were increased,the observation group was higher than the control group,the level of CD8+was decreased,and the observation group was lower than the control group(P<0.05).The levels of tumor markers in the two groups before treatment were compared(P>0.05).After 2 and 6 cycles of treatment,carcinoembryonic antigen,carbohydrate antigen 125 and carbohydrate antigen 153 were decreased,and the observation group was lower than the control group(P<0.05).After 2 cycles of treatment,the pathological complete response(pCR)rate was 20.00%in the observation group and 5.00%in the control group.After 6 cycles of treatment,the pCR rate of the observation group was 32.50%,which was higher in the observation group than 12.50%in the control group(P<0.05).There was no signifi-cant difference in the incidence of rash,gastrointestinal reaction and other adverse reactions between the two groups(P>0.05).Conclusion The use of neoadjuvant chemotherapy with pertuzumab in the treatment of breast cancer patients has positive significance for the improvement of patients'immune function and tumor marker levels,promoting the increase of pathological complete response rate,havelower the incidence of ad-verse reactions,and ensuring the safety of the treatment.
维普
万方数据